help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 Click here to read this article as a CME course

First Published Online August 11, 2008
The Oncologist, Vol. 13, No. 8, 876-885, August 2008; doi:10.1634/theoncologist.2008-0061
© 2008 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
theoncologist.2008-0061v1
theoncologist.2008-0061v2
13/8/876    most recent
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McKibbin, T.
Right arrow Articles by Koeller, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McKibbin, T.
Right arrow Articles by Koeller, J. M.

Gastrointestinal Cancer

Disparities in the Use of Chemotherapy and Monoclonal Antibody Therapy for Elderly Advanced Colorectal Cancer Patients in the Community Oncology Setting

Trevor McKibbina, Christopher R. Freib,c, Rebecca E. Greeneb,c, Peter Kwanb, Jody Simond, Jim M. Koellerb,c

aUniversity of Tennessee Health Science Center, Memphis, Tennessee, USA; bUniversity of Texas at Austin College of Pharmacy, Austin, Texas, USA; cUniversity of Texas Health Science Center at San Antonio, San Antonio, Texas, USA; dGeriatric Oncology Consortium, Baltimore, Maryland, USA

Key Words. Colorectal cancer • Elderly • Bevacizumab • Oxaliplatin • Irinotecan • Disparity

Correspondence: Trevor McKibbin, Pharm.D., M.Sc., College of Pharmacy, University of Tennessee Health Science Center, 930 Madison Suite 890, Memphis, Tennessee 38163, USA. Telephone: 901-448-7632; Fax: 901-448-5419; e-mail: tmckibbi{at}utmem.edu

Received March 12, 2008; accepted for publication June 28, 2008; first published online in THE ONCOLOGIST Express on August 11, 2008.

Disclosure: T.McK. is on the advisory board for Genentech. J.M.K. is a speaker for Pfizer, MGI Pharma, Lilly, and Abraxis. He is also an advisor for Bristol-Myers Squibb, Sanofi Aventis, AstraZeneca, Genentech, and Pharmion. Pfizer Oncology provided support for conducting data collection. The sponsor was not involved in the design and conduct of the study, analysis or interpretation of the data, or preparation of the manuscript. The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the authors, planners, independent peer reviewers, or staff managers of the article.

Background. The clinical trials on which the treatment of advanced colorectal (CRC) is based enroll few elderly patients. Furthermore, few investigations have determined the use and outcomes of the treatment of advanced CRC in practice. This study evaluated the treatment of advanced CRC in community oncology practices, focusing on age-related differences in treatment and outcome.

Methods. A national, retrospective chart review was conducted to evaluate the management of advanced CRC in 10 community practices across the U.S. All medical records of patients diagnosed with advanced CRC initiating chemotherapy treatment after January 1, 2003 through 2006 were included. The primary aim was to compare the proportion receiving doublet chemotherapy (irinotecan or oxaliplatin with a fluoropyrimidine) as initial therapy in young (age ≤65 years) and elderly (age >65 years) patients. Additional aims included age-based comparisons of the addition of bevacizumab to chemotherapy, overall chemotherapy use, all-cause mortality, and toxicity-related events.

Results. Overall, 520 patients (56% elderly) received 6,253 cycles of chemotherapy. Of the younger patients, 84% received doublet chemotherapy first-line, compared with 58% of elderly patients (p < .001). The use of each of the medications—irinotecan, oxaliplatin, and bevacizumab—was lower in elderly patients (p < .001). Independent predictors of a higher risk for mortality were age >65 (adjusted hazards ratio [HR],1.19; 95% confidence interval [CI], 1.02–1.39) and performance status score ≥2 (HR, 1.65; 95% CI, 1.41–1.91).

Conclusion. Elderly patients are less likely to receive first-line doublet chemotherapy than younger patients. Age and performance status are independent predictors of treatment and overall survival.




This article has been cited by other articles:


Home page
 The OncologistHome page
M. Moore, S. Kosmider, K. Field, J. Desai, L. Lim, F. Barnett, and P. Gibbs
Response to "Disparities in the Use of Chemotherapy and Monoclonal Antibody Therapy for Elderly Advanced Colorectal Cancer Patients in the Community Oncology Setting"
Oncologist, January 1, 2009; 14(1): 104 - 105.
[Full Text] [PDF]

Home page
 The OncologistHome page
T. McKibbin and J. M. Koeller
In Reply
Oncologist, January 1, 2009; 14(1): 106 - 107.
[Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2008 by AlphaMed Press.